Based on the ECCO consensus guidelines on medication safety during... | Download Table
Adalimumab | ECCO E-Guide
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
ECCO-EFCCA Patient Guidelines on Crohn's Disease (CD)
PDF) Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: Medical treatment
Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease - Gastroenterology
Neel Heerasing (@gastrodr_nh) / Twitter
European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy
European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy
Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost‐effectiveness analysis - Yao - 2021 - Journal of Gastroenterology and Hepatology - Wiley Online Library
European Crohn´s and Colitis Organisation - ECCO - DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 | SpringerLink
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY) - Gastroenterology
![PDF] [Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics]. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0a8e924d287b22861a1cb440f147aa0618dbc982/2-Table1-1.png "PDF] [Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics]. | Semantic Scholar")
PDF] [Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics]. | Semantic Scholar
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease | Gastroenterología y Hepatología (English Edition)
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
Children | Free Full-Text | Therapy Strategies for Children Suffering from Inflammatory Bowel Disease (IBD)—A Narrative Review | HTML
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra
Managing complex perianal disease after anti-TNF failure: Where to go next? - ScienceDirect
PDF) DOP064 ECCO expert consensus and topical review on treatment exit strategies in inflammatory bowel disease
European Crohn´s and Colitis Organisation - ECCO - P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice
Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients | Scientific Reports
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020 | SpringerLink
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study - The Lancet Gastroenterology & Hepatology
Treatment Algorithms for Crohn's Disease - FullText - Digestion 2020, Vol. 101, Suppl. 1 - Karger Publishers
Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring - Gastroenterology
Adalimumab | ECCO E-Guide
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? | Nature Reviews Gastroenterology & Hepatology
